Iovance Biotherapeutics Inc. (IOVA): $8.13
Market Cap: $2.08B
EV: $1.8B
Seeing Merrimack Pharmaceuticals Inc (MACK) on the list of the top 5 insider purchases last week, I was reminded of our coverage of another pharmaceutical company Iovance Biotherapeutics (IOVA) that we wrote about in an Insider Weekends article in September of this year. I have reproduced what we wrote about both companies in that article and have a follow-up section discussing recent developments:
We rarely dive into a biotech company for an Insider Weekends article, and it’s even rarer that we write about a clinical-stage biotechnology company. However, on certain occasions, we find some sort of special situation that makes the company worth exploring, as was the case with the cluster of insider purchases at Merrimack Pharmaceuticals (MACK), about which we wrote the following in January: